Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX in TNBC
NCT02897050Phase 2Suspended
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2016
- Primary completion
- Dec 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine and cyclophosphamide in triple-negative breast cancer (TNBC) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Pathological Complete Response Rate. Started Sep 2016; status: suspended.
02
Drugs
capecitabinecyclophosphamide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02897050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02897050.